Docetaxel Kabi is a cancer medicine used to treat the following types of cancer: - breast cancer. Docetaxel Kabi can be used on its own after other treatments have failed. It can also be used with other cancer medicines (capecitabine, cyclophosphamide, doxorubicin or trastuzumab) in patients who have not yet received treatment for their cancer or after other treatments have failed, depending on the type and stage of the breast cancer being treated; - non‑small-cell lung cancer. Docetaxel Kabi can be used on its own after other treatments have failed. It can also be used with cisplatin (another cancer medicine) in patients who have not yet received any treatment for their cancer; - prostate cancer that has spread to other parts of the body (metastatic). Docetaxel Kabi is used with androgen-deprivation therapy (therapy greatly reducing the body’s production of testosterone) when such treatment still works. Docetaxel Kabi is used with prednisone or prednisolone (anti-inflammatory medicines) when the cancer is castration resistant (androgen-deprivation therapy does not work); - metastatic gastric adenocarcinoma (a stomach cancer) in patients who have not yet received any treatment for metastatic cancer. Docetaxel Kabi is used with cisplatin and fluorouracil (other cancer medicines); - head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread). Docetaxel Kabi is used with cisplatin and fluorouracil. Docetaxel Kabi is a ‘generic medicine’. This means that Docetaxel Kabi is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Taxotere. Docetaxel Kabi contains the active substance docetaxel.
Therapeutic Indication
### Therapeutic indication **Breast cancer** Docetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: - operable node-positive breast cancer; - operable node-negative breast cancer. For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer. Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. **Non-small-cell lung cancer** Docetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy. Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition. **Prostate cancer** Docetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer. Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer. **Gastric adenocarcinoma** Docetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. **Head and neck cancer** Docetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Therapeutic Area (MeSH)
N/AATC Code
L01CD02
ATC Item
docetaxel
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| docetaxel | N/A | 多西他赛 |
EMA Name
Docetaxel Kabi
Medicine Name
Docetaxel Kabi
Aliases
N/ANo risk management plan link.
